BioSpace Presents the World Atlas of GLP-1s

BioSpace Presents the World Atlas of GLP-1s:
A Global Battle for Weight Loss Dominance

Eli Lilly and Novo Nordisk are engaged in a worldwide competition for supremacy in the weight loss market, with their GLP-1 drugs gaining approvals and launching in various countries10. Here's an overview of their global presence and strategic moves:

United States

Both companies have resolved manufacturing issues that initially hindered the rollout of GLP-1 drugs for weight loss10.
Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) are approved and available10.

Europe

European Medicines Agency approved Wegovy in January 2022 and Mounjaro (tirzepatide) for weight management in June 202410.
Wegovy has launched in France, Germany, Norway, Spain, Italy, Switzerland, Iceland, Denmark, and the UK10.
Zepbound is currently only available in Poland10.

Asia

- India:
Eli Lilly recently won approval for tirzepatide, marketed as Mounjaro10.

- China:
Wegovy launched in November 2024, while Lilly conducted a limited launch in 2024 with plans to expand10.

- Japan:
Wegovy is available10.

Other Regions

Wegovy has launched in Brazil, Australia, United Arab Emirates, and Canada10.
Lilly plans to launch tirzepatide in Brazil and Mexico10.

Market Strategies

- India pricing:
Lilly has priced the drug at $200 for a month's supply, compared to $483 in China and a U.S. list price of about $1,087.37 per fill10.
- Leerink Partners analysts estimate 718 million addressable patients in China and India combined10.
- Novo Nordisk targets an India launch in 2026, giving Lilly a one-year head start10.

Future Outlook

Lilly expects increased revenue from China, India, Brazil, and Mexico in the second half of 2025 and into 202610.
Both companies continue to manage global launches and promotions due to supply constraints10.

This global expansion of GLP-1 drugs for weight loss demonstrates the significant market potential and fierce competition between Eli Lilly and Novo Nordisk in addressing the growing worldwide demand for effective obesity treatments.

Sources:

10. https://www.biospace.com/business/biospace-presents-the-world-atlas-of-glp-1s